Investors & MediaVectivBio AG is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. We are committed to pursuing severe rare diseases with well-defined biology that can be targeted with therapies that have the potential to meaningfully transform and improve the lives of patients.
Recent News and Upcoming Events
Apr 13, 2021
VectivBio Announces Closing of $146.6 Million Initial Public Offering
BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a